PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2019; 119(10): 1554-1562
DOI: 10.1055/s-0039-1693411
Theme Issue Article
Georg Thieme Verlag KG Stuttgart · New York

Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease

Koichi Kaikita
1   Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
,
Kazuya Hosokawa
2   Research Institute, Fujimori Kogyo Co., Yokohama, Kanagawa, Japan
,
Jeffrey R. Dahlen
3   Hikari Dx, San Diego, California, United States
,
Kenichi Tsujita
1   Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
› Institutsangaben Funding This study was supported in part by Grants-in-Aid for Scientific Research (#15K09089) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Weitere Informationen

Publikationsverlauf

23. Dezember 2018

29. Mai 2019

Publikationsdatum:
22. Juli 2019 (online)

    Lizenzen und Reprints

Erratum zu diesem Artikel:

ErratumThromb Haemost 2019; 119(10): e1-e1
DOI: 10.1055/s-0040-1702204

Abstract

Various antithrombotic agents are clinically used to inhibit the cascade of arterial or venous thrombosis in cardiovascular diseases. Dual antiplatelet therapy with aspirin and P2Y12 inhibitors is prescribed in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Direct oral anticoagulants (DOACs) are widely used for the prevention or treatment of thromboembolism in patients with atrial fibrillation (AF) and venous thromboembolism. However, there has been no definitive tool to simultaneously monitor the antithrombotic effects of these drugs. The Total Thrombus-Formation Analysis System (T-TAS), a microchip-based flow chamber system that mimics in vivo conditions for evaluating whole blood thrombogenicity, was developed for the quantitative analysis of thrombus formation in whole blood specimens. The utility of T-TAS has been evaluated in CAD patients treated with antiplatelet therapies. The T-TAS PL chip area under the flow pressure curve (AUC) accurately assesses primary hemostasis and is sensitive to the therapeutic effects of various antiplatelet therapies. In addition, low AUC results are a significant predictor of periprocedural bleeding events in CAD patients undergoing PCI. The T-TAS AR chip AUC result is useful for assessing the efficacy of DOACs and warfarin in AF patients undergoing catheter ablation, and it is also a potential independent predictor of periprocedural bleeding events and avoidance of thrombosis in patients having undergone total knee arthroplasty. In conclusion, T-TAS is a useful index for evaluating the total antithrombotic effects of combination antithrombotic agents in patients with various cardiovascular diseases.

Keywords

T-TAS - antiplatelet therapy - direct oral anticoagulants - antithrombotic therapy - diagnostic test
 

  • References

  • 1 Toschi V, Gallo R, Lettino M. , et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95 (03) 594-599
    CrossrefPubMedGoogle Scholar
  • 2 Rentrop KP. Thrombi in acute coronary syndromes: revisited and revised. Circulation 2000; 101 (13) 1619-1626
    CrossrefPubMedGoogle Scholar
  • 3 Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94 (08) 2013-2020
    CrossrefPubMedGoogle Scholar
  • 4 Leon MB, Baim DS, Popma JJ. , et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339 (23) 1665-1671
    CrossrefPubMedGoogle Scholar
  • 5 Urban P, Macaya C, Rupprecht HJ. , et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98 (20) 2126-2132
    CrossrefPubMedGoogle Scholar
  • 6 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
    CrossrefPubMedGoogle Scholar
  • 7 Mehta SR, Yusuf S, Peters RJ. , et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-533
    CrossrefPubMedGoogle Scholar
  • 8 Gerschutz GP, Bhatt DL. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events study. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?. Am Heart J 2003; 145 (04) 595-601
    CrossrefPubMedGoogle Scholar
  • 9 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedGoogle Scholar
  • 10 Saito S, Isshiki T, Kimura T. , et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78 (07) 1684-1692
    CrossrefPubMedGoogle Scholar
  • 11 Isshiki T, Kimura T, Ogawa H. , et al; PRASFIT-Elective Investigators. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 2014; 78 (12) 2926-2934
    CrossrefPubMedGoogle Scholar
  • 12 Airoldi F, Colombo A, Morici N. , et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116 (07) 745-754
    CrossrefPubMedGoogle Scholar
  • 13 Iakovou I, Schmidt T, Bonizzoni E. , et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293 (17) 2126-2130
    CrossrefPubMedGoogle Scholar
  • 14 Chen ZM, Jiang LX, Chen YP. , et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497): 1607-1621
    CrossrefPubMedGoogle Scholar
  • 15 Sabatine MS, Cannon CP, Gibson CM. , et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352 (12) 1179-1189
    CrossrefPubMedGoogle Scholar
  • 16 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 17 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 18 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 19 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 20 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 21 Nakamura M, Nishikawa M, Komuro I. , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circ J 2015; 79 (06) 1230-1236
    CrossrefPubMedGoogle Scholar
  • 22 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 23 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 24 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 25 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 26 Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28 (14) 1702-1708
    CrossrefPubMedGoogle Scholar
  • 27 Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29 (23) 2877-2885
    CrossrefPubMedGoogle Scholar
  • 28 Grove EL, Hvas AM, Johnsen HL. , et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103 (06) 1245-1253
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119 (19) 2625-2632
    CrossrefPubMedGoogle Scholar
  • 30 Harle CC. Point-of-care platelet function testing. Semin Cardiothorac Vasc Anesth 2007; 11 (04) 247-251
    CrossrefPubMedGoogle Scholar
  • 31 Harrison P. Assessment of platelet function in the laboratory. Hamostaseologie 2009; 29 (01) 25-31
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 32 Smith JW, Steinhubl SR, Lincoff AM. , et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99 (05) 620-625
    CrossrefPubMedGoogle Scholar
  • 33 Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106 (05) 1366-1375
    CrossrefPubMedGoogle Scholar
  • 34 Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5 (04) 886-888
    CrossrefPubMedGoogle Scholar
  • 35 Hosokawa K, Ohnishi T, Fukasawa M. , et al. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 2012; 83 (02) 154-161
    CrossrefPubMedGoogle Scholar
  • 36 Hosokawa K, Ohnishi T, Kondo T. , et al. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 2011; 9 (10) 2029-2037
    CrossrefPubMedGoogle Scholar
  • 37 Sueta D, Kaikita K, Okamoto N. , et al. A novel quantitative assessment of whole blood thrombogenicity in patients treated with a non-vitamin K oral anticoagulant. Int J Cardiol 2015; 197: 98-100
    CrossrefPubMedGoogle Scholar
  • 38 Yamaguchi Y, Moriki T, Igari A. , et al. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res 2013; 132 (02) 263-270
    CrossrefPubMedGoogle Scholar
  • 39 Sueta D, Kaikita K, Ogawa H. Letter by Sueta et al Regarding Article, “Urgent Need to Measure Effects of Direct Oral Anticoagulants”. Circulation 2016; 134 (21) e496-e497
    PubMedGoogle Scholar
  • 40 Hosokawa K, Ohnishi T, Sameshima H. , et al. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. PLoS One 2014; 9 (01) e86491
    CrossrefPubMedGoogle Scholar
  • 41 Hosokawa K, Ohnishi T, Miura N. , et al. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thromb Res 2014; 133 (01) 66-72
    CrossrefPubMedGoogle Scholar
  • 42 Arima Y, Kaikita K, Ishii M. , et al. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost 2016; 14 (04) 850-859
    CrossrefPubMedGoogle Scholar
  • 43 Yasue H, Ogawa H, Tanaka H. , et al; Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol 1999; 83 (09) 1308-1313
    CrossrefPubMedGoogle Scholar
  • 44 Frelinger III AL, Bhatt DL, Lee RD. , et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013; 61 (08) 872-879
    CrossrefPubMedGoogle Scholar
  • 45 Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103 (3, Suppl): 27A-34A
    CrossrefPubMedGoogle Scholar
  • 46 Hollopeter G, Jantzen HM, Vincent D. , et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409 (6817): 202-207
    CrossrefPubMedGoogle Scholar
  • 47 Mega JL, Close SL, Wiviott SD. , et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (04) 354-362
    CrossrefPubMedGoogle Scholar
  • 48 Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008; 156 (2 Suppl): S16-S22
    CrossrefPubMedGoogle Scholar
  • 49 Ogawa H, Hokimoto S, Kaikita K. , et al. Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors. J Cardiol 2011; 58 (01) 6-17
    PubMedGoogle Scholar
  • 50 Ono T, Kaikita K, Hokimoto S. , et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res 2011; 128 (06) e130-e136
    CrossrefPubMedGoogle Scholar
  • 51 Kaikita K, Ono T, Iwashita S. , et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2014; 21 (01) 64-76
    PubMedGoogle Scholar
  • 52 Kaikita K, Yoshimura H, Ishii M. , et al; CALDERA-GENE Investigators. Tailored adjunctive cilostazol therapy based on CYP2C19 genotyping in patients with acute myocardial infarction – the CALDERA-GENE study. Circ J 2018; 82 (06) 1517-1525
    CrossrefPubMedGoogle Scholar
  • 53 Yamamoto K, Hokimoto S, Chitose T. , et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011; 57 (02) 194-201
    PubMedGoogle Scholar
  • 54 Price MJ, Angiolillo DJ, Teirstein PS. , et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124 (10) 1132-1137
    CrossrefPubMedGoogle Scholar
  • 55 Hosokawa K, Ohnishi T, Sameshima H. , et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 2013; 109 (01) 102-111
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 56 Yamazaki M, Ohnishi T, Hosokawa K. , et al. Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. J Thromb Haemost 2016; 14 (09) 1788-1797
    CrossrefPubMedGoogle Scholar
  • 57 Kwok CS, Khan MA, Rao SV. , et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv 2015; 8 (04) e001645
    PubMedGoogle Scholar
  • 58 Rao SV, Dai D, Subherwal S. , et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv 2012; 5 (09) 958-965
    CrossrefPubMedGoogle Scholar
  • 59 Feit F, Voeltz MD, Attubato MJ. , et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100 (09) 1364-1369
    CrossrefPubMedGoogle Scholar
  • 60 Kwok CS, Rao SV, Myint PK. , et al. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. Open Heart 2014; 1 (01) e000021
    CrossrefPubMedGoogle Scholar
  • 61 Kinnaird TD, Stabile E, Mintz GS. , et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92 (08) 930-935
    CrossrefPubMedGoogle Scholar
  • 62 Subherwal S, Peterson ED, Dai D. , et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. J Am Coll Cardiol 2012; 59 (21) 1861-1869
    CrossrefPubMedGoogle Scholar
  • 63 Vora AN, Rao SV. Bleeding complications after PCI and the role of transradial access. Curr Treat Options Cardiovasc Med 2014; 16 (05) 305
    CrossrefPubMedGoogle Scholar
  • 64 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 65 Saito S, Isshiki T, Kimura T. , et al; PRASFIT-ACS and PRASFIT-Elective Investigators. Impact of arterial access route on bleeding complications in Japanese patients undergoing percutaneous coronary intervention- insight from the PRASFIT trial. Circ J 2015; 79 (09) 1928-1937
    CrossrefPubMedGoogle Scholar
  • 66 Oimatsu Y, Kaikita K, Ishii M. , et al. Total thrombus-formation analysis system predicts periprocedural bleeding events in patients with coronary artery disease undergoing percutaneous coronary intervention. J Am Heart Assoc 2017; 6 (04) e005263
    PubMedGoogle Scholar
  • 67 Borst O, Münzer P, Alnaggar N. , et al. Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Adv 2018; 2 (06) 715-730
    CrossrefPubMedGoogle Scholar
  • 68 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 69 López-López JA, Sterne JAC, Thom HHZ. , et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
    CrossrefPubMedGoogle Scholar
  • 70 Komori M, Yasaka M, Kokuba K. , et al. Intracranial hemorrhage during dabigatran treatment. Circ J 2014; 78 (06) 1335-1341
    CrossrefPubMedGoogle Scholar
  • 71 Suzuki S, Sagara K, Otsuka T. , et al. “Blue letter effects”: changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. J Cardiol 2013; 62 (06) 366-373
    PubMedGoogle Scholar
  • 72 Ogawa S, Koretsune Y, Yasaka M. , et al. Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. Circ J 2011; 75 (07) 1539-1547
    CrossrefPubMedGoogle Scholar
  • 73 Ito M, Kaikita K, Sueta D. , et al. Total Thrombus-formation Analysis System (T-TAS) can predict periprocedural bleeding events in patients undergoing catheter ablation for atrial fibrillation. J Am Heart Assoc 2016; 5 (01) e002744
    PubMedGoogle Scholar
  • 74 Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): 7S-47S
    CrossrefPubMedGoogle Scholar
  • 75 Group JCSJW. ; JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011; 75 (05) 1258-1281
    CrossrefPubMedGoogle Scholar
  • 76 Sueta D, Kaikita K, Okamoto N. , et al. Efficacy study of the combination of edoxaban and physiotherapy on the prevention of venous-thromboembolism in patients after total knee arthroplasty (ESCORT-TKA trial): study protocol for a randomized controlled trial. Clin Trials Regul Sci Cardiol 2016; 19: 1-4
    PubMedGoogle Scholar
  • 77 Sueta D, Kaikita K, Okamoto N. , et al; ESCORT-TKA Study Investigators. Edoxaban enhances thromboprophylaxis by physiotherapy after total knee arthroplasty- the randomized controlled ESCORT-TKA trial. Circ J 2018; 82 (02) 524-531
    CrossrefPubMedGoogle Scholar
  • 78 Gibson CM, Mehran R, Bode C. , et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
    CrossrefPubMedGoogle Scholar
  • 79 Cannon CP, Bhatt DL, Oldgren J. , et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377 (16) 1513-1524
    CrossrefPubMedGoogle Scholar